Arrowhead Pharmaceuticals, Inc. (ARWR:NASDAQ) closed at $58.36 on October 22, 2026, down 0.82% on the day. The stock trades 38.9% below its 52-week high of $95.49 and 58.9% above its 52-week low of $36.73. Over the past year, it gained 56.3%. Arrowhead Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 22, 2025, ARWR closed higher on 124 days (49%). Its best day was November 26, 2025 (+23.34%) and its worst was September 15, 2026 (-12.40%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 2 times.
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Find more stocks like ARWR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.